A Bayesian approach to aid in formulary decision making: Incorporating institution-specific cost-effectiveness data with clinical trial results

Medical Decision Making

Volumn 23, Issue 3, 2003, Pages 252-264

  Reed, Shelby D ^a,b   Dillingham, Peter W ^c   Briggs, Andrew H ^d   Veenstra, David L ^a   Sullivan, Sean D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bayesian analysis; Cost effectiveness; Decision making; Formulary decision making; Monte Carlo simulation

Indexed keywords

ABCIXIMAB;

ADULT; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DECISION THEORY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; PHARMACY AND THERAPEUTICS COMMITTEE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BAYES THEOREM; CORONARY ARTERY BYPASS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS;

EID: 0037799605     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X03023003007     Document Type: Article

References (35)

1. Powe NR, Griffiths RI. The clinical-economic trial: promise, problems, and challenges. Control Clin Trials. 1995;16:377-94.
2. Schulman KA, Glick H, Buxton M, et al. The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Control Clin Trial. 1996;17:304-15.
3. O'Brien BJ, Drummond MF, LaBelle RJ, Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care. 1994;32:150-63.
4. Frieman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, type II error and sample size in the randomized control trial: survey of 71 "negative" trials. N Engl J Med. 1978;299:690-4.
5. Laska EM, Meisner M, Siegel C. Statistical inference for cost-effectiveness ratios. Health Econ. 1997;6:229-42.
6. Cook JR, Heyse JF. Use of an angular transformation for ratio estimation in cost-effectiveness analysis. Statist Med. 2000;19:2989-3003.
7. Heitjan DF, Moskowitz AJ, Whang W. Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ. 1999;8:191-201.
8. Reed SD, Mullins CD, Magder LS. Cost-effectiveness of abciximab during routine medical practice. Pharmacoeconomics. 2000;18:265-74.
9. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-61.
10. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
11. Gu XS, Rosenbaum PR. Comparison of multivariate matching methods: structures, distances and algorithims. J Comput Graph Stat. 1993;2:405-20.
12. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-24.
13. Rosenbaum PR. Conditional permutation tests and the propensity score in observational studies. J Am Stat Assoc. 1984;79:565-74.
14. Robins JM, Mark SD, Newey WK. Estimating exposure effects by modelling the expectation of exposure conditional on confounders. Biometrics. 1992;48:479-95.
15. Little RJ, Rubin DB. Causal effects in clinical and epidemiologic studies via potential outcomes: concepts and analytical approaches. Ann Rev Public Health. 2000;21:121-45.
16. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation. 1990;82:1193-1202.
17. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Statistician. 1985;39:33-8.
18. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-96.
19. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
20. Serruys PW, De Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-95.
21. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496-501.
22. Stangl DK, Berry DA. Meta-analysis: past and present challenges. In: Stangl DK, Berry DA, editors. Meta-Analysis in Medicine and Health Policy. New York: Marcel Dekker; 2000. p. 1-28.
23. Brophy JM, Lawrence J, Rouleau JL. β-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med. 2001;134:550-60.
24. Gelman A, Carlin JB, Stern H, Rubin DB. Bayesian Data Analysis. New York: Chapman and Hall; 1995.
25. Smith TC, Spiegelhalter DJ, Parmar MKB. Bayesian meta-analysis of randomized trials using graphical models and BUGS. In: Berry DA, Stangl DK, editors. Bayesian Biostatistics. New York: Marcel Dekker; 2000. p. 411-27.
26. Spiegelhalter DJ, Thomas A, Best NG, Gilks WR. WinBUGS: Bayesian Inference Using Gibbs Sampling, Version 1.2. Cambridge, UK: MRC Biostatistics Unit; 1999.
27. Eeckhout E, Wijns W, Meier B, Goy JJ. Indications for intracoronary stent placement: the European view. Working Group on Coronary Circulation of the European Society of Cardiology. Eur Heart J. 1999;20:1014-9.
28. Boersma H, van der Vlugt MJ, Arnold AER, Deckers JW, Simoons ML. Estimated gain in life expectancy: a simple tool to select optimal reperfusion treatment in individual patients with evolving myocardial infarction. Eur Heart J. 1996;17:64-75.
29. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(suppl 2):S65-80.
30. Savage MP, Douglas JS, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med. 1997;337:740-7.
31. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18:341-64.
32. Claxton K, Neumann PJ, Araki S, Weinstein MC. Bayesian value-of-information analysis: an application to a policy model of Alzheimer's disease. Int J Technol Assess Health Care. 2001;17:38-55.
33. Altman DG. Comparability of randomized groups. Statistician. 1985;34:125-36.
34. Rittenhouse BE. The relevance of searching for effects under a clinical trial lamppost: a key issue. Med Decis Making. 1995;15:348-57.
35. Rittenhouse BE. Exorcising protocol-induced spirits: making the clinical trial relevant for economics. Med Decis Making. 1997;17:331-9.